Cost variation analysis of statins available in India

Ashika Arka Gopalakrishna, N. Bose, S. Stanly
{"title":"Cost variation analysis of statins available in India","authors":"Ashika Arka Gopalakrishna, N. Bose, S. Stanly","doi":"10.18203/2319-2003.ijbcp20214114","DOIUrl":null,"url":null,"abstract":"Background: The current study aimed to find out the percentage cost variation among the various brands of statins marketed in India. Statins are HMG-CoA reductase inhibitors which are widely prescribed as blood cholesterol lowering agents and hence reduce illness and mortality in those who are at high risk of cardiovascular disease. There are numerous brands of statins are marketed in India.Methods: Cost of a particular drug manufactured by different companies in the same strength and the dosage form was obtained from the price list provided by the pharmaceutical companies in current index of medical specialities (CIMS) (42nd year January to April 2021). The difference in the maximum and the minimum price of the same drug manufactured by different pharmaceutical companies, cost ratio and the percentage variation in price were analysed.Results: The percentage cost variation of statins was seen highest with tablet atorvastatin 20 mg (564.06%), followed by combination of capsule atorvastatin 10 mg+aspirin 75 mg (325%) which was followed by combination of film coated tablet atorvastatin 10 mg+fenofibrate 160 mg (267.4%), tablet rosuvastatin 20 mg (171.1%), tablet lovastatin 10 mg (108.9%), combination of tablet rosuvastatin 10 mg+fenofibrate 160 mg (87.34%) and lowest was seen with tablet simvastatin 20 mg (6.0%).Conclusions: There is a very wide cost variation among different brands of statins marketed in India. The percentage cost variation was found to be the highest among the moderate intensity statins. ","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Basic & Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2319-2003.ijbcp20214114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The current study aimed to find out the percentage cost variation among the various brands of statins marketed in India. Statins are HMG-CoA reductase inhibitors which are widely prescribed as blood cholesterol lowering agents and hence reduce illness and mortality in those who are at high risk of cardiovascular disease. There are numerous brands of statins are marketed in India.Methods: Cost of a particular drug manufactured by different companies in the same strength and the dosage form was obtained from the price list provided by the pharmaceutical companies in current index of medical specialities (CIMS) (42nd year January to April 2021). The difference in the maximum and the minimum price of the same drug manufactured by different pharmaceutical companies, cost ratio and the percentage variation in price were analysed.Results: The percentage cost variation of statins was seen highest with tablet atorvastatin 20 mg (564.06%), followed by combination of capsule atorvastatin 10 mg+aspirin 75 mg (325%) which was followed by combination of film coated tablet atorvastatin 10 mg+fenofibrate 160 mg (267.4%), tablet rosuvastatin 20 mg (171.1%), tablet lovastatin 10 mg (108.9%), combination of tablet rosuvastatin 10 mg+fenofibrate 160 mg (87.34%) and lowest was seen with tablet simvastatin 20 mg (6.0%).Conclusions: There is a very wide cost variation among different brands of statins marketed in India. The percentage cost variation was found to be the highest among the moderate intensity statins. 
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
印度可用他汀类药物的成本变化分析
背景:本研究旨在找出在印度销售的不同品牌的他汀类药物的成本变化百分比。他汀类药物是HMG-CoA还原酶抑制剂,被广泛用作降低血液胆固醇的药物,从而减少心血管疾病高危人群的疾病和死亡率。有许多品牌的他汀类药物在印度销售。方法:从医药企业提供的现行医学专业指数(CIMS)(第42年1月至2021年4月)价目表中获取不同企业生产的同一强度和剂型的某一药品的成本。分析了不同制药企业生产的同一种药品的最高、最低价格差异、成本比和价格变动百分比。结果:他汀类药物成本变化百分比以阿托伐他汀片20 mg最高(564.06%),其次为阿托伐他汀胶囊10 mg+阿司匹林75 mg(325%),其次为阿托伐他汀包膜片10 mg+非诺贝特160 mg(267.4%)、瑞舒伐他汀片20 mg(171.1%)、洛伐他汀片10 mg(108.9%)、瑞舒伐他汀片10 mg+非诺贝特160 mg(87.34%),辛伐他汀片20 mg最低(6.0%)。结论:在印度,不同品牌的他汀类药物的成本差异很大。在中等强度的他汀类药物中,成本变化百分比最高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review Efficacy of current treatments against hepatitis C virus Adverse drug reactions to first line anti-tuberculosis drugs in newly diagnosed tuberculosis patients Comparing the effect of statins on hepatic fibrosis induced by carbon tetrachloride in Wistar rats Prescription audit of antihypertensive drugs used in stroke patients in a tertiary care teaching hospital
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1